WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	50.15B
Revenue (ttm)	4.31B
Net Income (ttm)	1.14B
Shares Out	1.20B
EPS (ttm)	0.88
PE Ratio	47.21
Forward PE	31.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,261,566
Average Volume	5,275,263
Open	41.40
Previous Close	41.00
Day's Range	40.20 - 42.10
52-Week Range	14.08 - 49.50
Beta	n/a
RSI	58.35
Earnings Date	May 21, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. The company engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It provides international sales contracting, biologics discovery, development, and manufacturing services. The company...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 2,041
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY